Renal Denervation Devices Market Size to Hit USD 4.49 Billion by 2034

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Renal Denervation Devices Market

5.1. COVID-19 Landscape: Renal Denervation Devices Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Renal Denervation Devices Market, By Technology/Energy Source

8.1. Renal Denervation Devices Market Revenue and Volume, by Technology/Energy Source

8.1.1. Radiofrequency (RF) ablation systems (multi-electrode and spiral catheters + generators)

8.1.1.1. Market Revenue and Volume Forecast

8.1.2. Ultrasound-based RDN systems (circumferential sonication catheters + consoles)

8.1.2.1. Market Revenue and Volume Forecast

8.1.3. Chemical/neurolytic denervation (injectable agents/chemical ablation catheters)

8.1.3.1. Market Revenue and Volume Forecast

8.1.4. Pulsed-field/electroporation and other emerging energy modalities

8.1.4.1. Market Revenue and Volume Forecast

Chapter 9. Global Renal Denervation Devices Market, By Product Type/System Component

9.1. Renal Denervation Devices Market Revenue and Volume, by Product Type/System Component

9.1.1. Disposable catheters (single-use renal denervation catheters)

9.1.1.1. Market Revenue and Volume Forecast

9.1.2. Procedural generators/energy consoles (reusable capital equipment)

9.1.2.1. Market Revenue and Volume Forecast

9.1.3. Procedure kits and consumables (sheaths, guidewires, cooling/infusion sets)

9.1.3.1. Market Revenue and Volume Forecast

9.1.4. Software and mapping/registration aids (procedure planning and reporting)

9.1.4.1. Market Revenue and Volume Forecast

Chapter 10. Global Renal Denervation Devices Market, By Procedure Approach/Clinical Technique

10.1. Renal Denervation Devices Market Revenue and Volume, by Procedure Approach/Clinical Technique

10.1.1. Main renal-artery ablation only (standard technique)

10.1.1.1. Market Revenue and Volume Forecast

10.1.2. Main artery + distal/branch ablation (extended denervation)

10.1.2.1. Market Revenue and Volume Forecast

10.1.3. Bilateral vs unilateral procedures

10.1.3.1. Market Revenue and Volume Forecast

10.1.4. Staged/repeat denervation procedures

10.1.4.1. Market Revenue and Volume Forecast

Chapter 11. Global Renal Denervation Devices Market, By Indication/Clinical Use

11.1. Renal Denervation Devices Market Revenue and Volume, by Indication/Clinical Use

11.1.1. Resistant/uncontrolled hypertension (adjunct to meds)

11.1.1.1. Market Revenue and Volume Forecast

11.1.2. Routine hypertension management (med-reduction strategies)

11.1.2.1. Market Revenue and Volume Forecast

11.1.3. Chronic kidney disease (CKD) with hypertension (investigational/adjunct)

11.1.3.1. Market Revenue and Volume Forecast

11.1.4. Other sympathetic-driven indications (heart failure, arrhythmia adjuncts — investigational)

11.1.4.1. Market Revenue and Volume Forecast

Chapter 12. Global Renal Denervation Devices Market, By End-User/Buyer

12.1. Renal Denervation Devices Market Revenue and Volume, by End-User/Buyer

12.1.1. Interventional cardiology departments/cardiologists

12.1.1.1. Market Revenue and Volume Forecast

12.1.2. Vascular surgery and interventional radiology units

12.1.2.1. Market Revenue and Volume Forecast

12.1.3. Hypertension specialty clinics and integrated health systems

12.1.3.1. Market Revenue and Volume Forecast

12.1.4. Hospitals (capital procurement) vs private clinics (procedure buyers)

12.1.4.1. Market Revenue and Volume Forecast

Chapter 13. Global Renal Denervation Devices Market, Regional Estimates and Trend Forecast

13.1. North America

13.1.1. Market Revenue and Volume Forecast, by Technology/Energy Source

13.1.2. Market Revenue and Volume Forecast, by Product Type/System Component

13.1.3. Market Revenue and Volume Forecast, by Procedure Approach/Clinical Technique

13.1.4. Market Revenue and Volume Forecast, by Indication/Clinical Use

13.1.5. Market Revenue and Volume Forecast, by End-User/Buyer

13.1.6. U.S.

13.1.6.1. Market Revenue and Volume Forecast, by Technology/Energy Source

13.1.6.2. Market Revenue and Volume Forecast, by Product Type/System Component

13.1.6.3. Market Revenue and Volume Forecast, by Procedure Approach/Clinical Technique

13.1.6.4. Market Revenue and Volume Forecast, by Indication/Clinical Use

13.1.6.5. Market Revenue and Volume Forecast, by End-User/Buyer

13.1.7. Rest of North America

13.1.7.1. Market Revenue and Volume Forecast, by Technology/Energy Source

13.1.7.2. Market Revenue and Volume Forecast, by Product Type/System Component

13.1.7.3. Market Revenue and Volume Forecast, by Procedure Approach/Clinical Technique

13.1.7.4. Market Revenue and Volume Forecast, by Indication/Clinical Use

13.1.7.5. Market Revenue and Volume Forecast, by End-User/Buyer

13.2. Europe

13.2.1. Market Revenue and Volume Forecast, by Technology/Energy Source

13.2.2. Market Revenue and Volume Forecast, by Product Type/System Component

13.2.3. Market Revenue and Volume Forecast, by Procedure Approach/Clinical Technique

13.2.4. Market Revenue and Volume Forecast, by Indication/Clinical Use

13.2.5. Market Revenue and Volume Forecast, by End-User/Buyer

13.2.6. UK

13.2.6.1. Market Revenue and Volume Forecast, by Technology/Energy Source

13.2.6.2. Market Revenue and Volume Forecast, by Product Type/System Component

13.2.6.3. Market Revenue and Volume Forecast, by Procedure Approach/Clinical Technique

13.2.7. Market Revenue and Volume Forecast, by Indication/Clinical Use

13.2.8. Market Revenue and Volume Forecast, by End-User/Buyer

13.2.9. Germany

13.2.9.1. Market Revenue and Volume Forecast, by Technology/Energy Source

13.2.9.2. Market Revenue and Volume Forecast, by Product Type/System Component

13.2.9.3. Market Revenue and Volume Forecast, by Procedure Approach/Clinical Technique

13.2.10. Market Revenue and Volume Forecast, by Indication/Clinical Use

13.2.11. Market Revenue and Volume Forecast, by End-User/Buyer

13.2.12. France

13.2.12.1. Market Revenue and Volume Forecast, by Technology/Energy Source

13.2.12.2. Market Revenue and Volume Forecast, by Product Type/System Component

13.2.12.3. Market Revenue and Volume Forecast, by Procedure Approach/Clinical Technique

13.2.12.4. Market Revenue and Volume Forecast, by Indication/Clinical Use

13.2.13. Market Revenue and Volume Forecast, by End-User/Buyer

13.2.14. Rest of Europe

13.2.14.1. Market Revenue and Volume Forecast, by Technology/Energy Source

13.2.14.2. Market Revenue and Volume Forecast, by Product Type/System Component

13.2.14.3. Market Revenue and Volume Forecast, by Procedure Approach/Clinical Technique

13.2.14.4. Market Revenue and Volume Forecast, by Indication/Clinical Use

13.2.15. Market Revenue and Volume Forecast, by End-User/Buyer

13.3. APAC

13.3.1. Market Revenue and Volume Forecast, by Technology/Energy Source

13.3.2. Market Revenue and Volume Forecast, by Product Type/System Component

13.3.3. Market Revenue and Volume Forecast, by Procedure Approach/Clinical Technique

13.3.4. Market Revenue and Volume Forecast, by Indication/Clinical Use

13.3.5. Market Revenue and Volume Forecast, by End-User/Buyer

13.3.6. India

13.3.6.1. Market Revenue and Volume Forecast, by Technology/Energy Source

13.3.6.2. Market Revenue and Volume Forecast, by Product Type/System Component

13.3.6.3. Market Revenue and Volume Forecast, by Procedure Approach/Clinical Technique

13.3.6.4. Market Revenue and Volume Forecast, by Indication/Clinical Use

13.3.7. Market Revenue and Volume Forecast, by End-User/Buyer

13.3.8. China

13.3.8.1. Market Revenue and Volume Forecast, by Technology/Energy Source

13.3.8.2. Market Revenue and Volume Forecast, by Product Type/System Component

13.3.8.3. Market Revenue and Volume Forecast, by Procedure Approach/Clinical Technique

13.3.8.4. Market Revenue and Volume Forecast, by Indication/Clinical Use

13.3.9. Market Revenue and Volume Forecast, by End-User/Buyer

13.3.10. Japan

13.3.10.1. Market Revenue and Volume Forecast, by Technology/Energy Source

13.3.10.2. Market Revenue and Volume Forecast, by Product Type/System Component

13.3.10.3. Market Revenue and Volume Forecast, by Procedure Approach/Clinical Technique

13.3.10.4. Market Revenue and Volume Forecast, by Indication/Clinical Use

13.3.10.5. Market Revenue and Volume Forecast, by End-User/Buyer

13.3.11. Rest of APAC

13.3.11.1. Market Revenue and Volume Forecast, by Technology/Energy Source

13.3.11.2. Market Revenue and Volume Forecast, by Product Type/System Component

13.3.11.3. Market Revenue and Volume Forecast, by Procedure Approach/Clinical Technique

13.3.11.4. Market Revenue and Volume Forecast, by Indication/Clinical Use

13.3.11.5. Market Revenue and Volume Forecast, by End-User/Buyer

13.4. MEA

13.4.1. Market Revenue and Volume Forecast, by Technology/Energy Source

13.4.2. Market Revenue and Volume Forecast, by Product Type/System Component

13.4.3. Market Revenue and Volume Forecast, by Procedure Approach/Clinical Technique

13.4.4. Market Revenue and Volume Forecast, by Indication/Clinical Use

13.4.5. Market Revenue and Volume Forecast, by End-User/Buyer

13.4.6. GCC

13.4.6.1. Market Revenue and Volume Forecast, by Technology/Energy Source

13.4.6.2. Market Revenue and Volume Forecast, by Product Type/System Component

13.4.6.3. Market Revenue and Volume Forecast, by Procedure Approach/Clinical Technique

13.4.6.4. Market Revenue and Volume Forecast, by Indication/Clinical Use

13.4.7. Market Revenue and Volume Forecast, by End-User/Buyer

13.4.8. North Africa

13.4.8.1. Market Revenue and Volume Forecast, by Technology/Energy Source

13.4.8.2. Market Revenue and Volume Forecast, by Product Type/System Component

13.4.8.3. Market Revenue and Volume Forecast, by Procedure Approach/Clinical Technique

13.4.8.4. Market Revenue and Volume Forecast, by Indication/Clinical Use

13.4.9. Market Revenue and Volume Forecast, by End-User/Buyer

13.4.10. South Africa

13.4.10.1. Market Revenue and Volume Forecast, by Technology/Energy Source

13.4.10.2. Market Revenue and Volume Forecast, by Product Type/System Component

13.4.10.3. Market Revenue and Volume Forecast, by Procedure Approach/Clinical Technique

13.4.10.4. Market Revenue and Volume Forecast, by Indication/Clinical Use

13.4.10.5. Market Revenue and Volume Forecast, by End-User/Buyer

13.4.11. Rest of MEA

13.4.11.1. Market Revenue and Volume Forecast, by Technology/Energy Source

13.4.11.2. Market Revenue and Volume Forecast, by Product Type/System Component

13.4.11.3. Market Revenue and Volume Forecast, by Procedure Approach/Clinical Technique

13.4.11.4. Market Revenue and Volume Forecast, by Indication/Clinical Use

13.4.11.5. Market Revenue and Volume Forecast, by End-User/Buyer

13.5. Latin America

13.5.1. Market Revenue and Volume Forecast, by Technology/Energy Source

13.5.2. Market Revenue and Volume Forecast, by Product Type/System Component

13.5.3. Market Revenue and Volume Forecast, by Procedure Approach/Clinical Technique

13.5.4. Market Revenue and Volume Forecast, by Indication/Clinical Use

13.5.5. Market Revenue and Volume Forecast, by End-User/Buyer

13.5.6. Brazil

13.5.6.1. Market Revenue and Volume Forecast, by Technology/Energy Source

13.5.6.2. Market Revenue and Volume Forecast, by Product Type/System Component

13.5.6.3. Market Revenue and Volume Forecast, by Procedure Approach/Clinical Technique

13.5.6.4. Market Revenue and Volume Forecast, by Indication/Clinical Use

13.5.7. Market Revenue and Volume Forecast, by End-User/Buyer

13.5.8. Rest of LATAM

13.5.8.1. Market Revenue and Volume Forecast, by Technology/Energy Source

13.5.8.2. Market Revenue and Volume Forecast, by Product Type/System Component

13.5.8.3. Market Revenue and Volume Forecast, by Procedure Approach/Clinical Technique

13.5.8.4. Market Revenue and Volume Forecast, by Indication/Clinical Use

13.5.8.5. Market Revenue and Volume Forecast, by End-User/Buyer

Chapter 14. Company Profiles

14.1. Ablative Solutions, Inc.

14.1.1. Company Overview

14.1.2. Product Offerings

14.1.3. Financial Performance

14.1.4. Recent Initiatives

14.2. Abbott

14.2.1. Company Overview

14.2.2. Product Offerings

14.2.3. Financial Performance

14.2.4. Recent Initiatives

14.3. Avinger/related interventional companies

14.3.1. Company Overview

14.3.2. Product Offerings

14.3.3. Financial Performance

14.3.4. Recent Initiatives

14.4. Boston Scientific Corporation

14.4.1. Company Overview

14.4.2. Product Offerings

14.4.3. Financial Performance

14.4.4. Recent Initiatives

14.5. Kona Medical, Inc

14.5.1. Company Overview

14.5.2. Product Offerings

14.5.3. Financial Performance

14.5.4. Recent Initiatives

14.6. Mercator MedSystems, Inc.

14.6.1. Company Overview

14.6.2. Product Offerings

14.6.3. Financial Performance

14.6.4. Recent Initiatives

14.7. Medtronic plc

14.7.1. Company Overview

14.7.2. Product Offerings

14.7.3. Financial Performance

14.7.4. Recent Initiatives

14.8. Neuravi/Renal-focused interventional firms

14.8.1. Company Overview

14.8.2. Product Offerings

14.8.3. Financial Performance

14.8.4. Recent Initiatives

14.9. PulseCath Technologies/investigational device firms

14.9.1. Company Overview

14.9.2. Product Offerings

14.9.3. Financial Performance

14.9.4. Recent Initiatives

14.10. ReCor Medical, Inc.

14.10.1. Company Overview

14.10.2. Product Offerings

14.10.3. Financial Performance

14.10.4. Recent Initiatives

Chapter 15. Research Methodology

15.1. Primary Research

15.2. Secondary Research

15.3. Assumptions

Chapter 16. Appendix

16.1. About Us

16.2. Glossary of Terms

For questions or customization requests, please reach out to us at sales@precedenceresearch.com

Frequently Asked Questions

The renal denervation devices market size is expected to increase from USD 1.13 billion in 2024 to USD 4.49 billion by 2034.

The renal denervation devices market is expected to grow at a compound annual growth rate (CAGR) of around 14.77% from 2025 to 2034.

The major players in the renal denervation devices market include Ablative Solutions, Inc., Abbott, Avinger/related interventional companies, Boston Scientific Corporation, Kona Medical, Inc, Mercator MedSystems, Inc., Medtronic plc, Neuravi/Renal-focused interventional firms, PulseCath Technologies/investigational device firm, ReCor Medical, Inc., Renal Dynamics Limited, SoniVie/CardioSonic(historical ultrasound/early programs), Symple Surgical, Inc., Terumo Corporation, and Vascular/specialty device firms offering RDN-capable platforms.

The driving factors of the renal denervation devices market are the rising prevalence of hypertension and increasing adoption of minimally invasive treatments for cardiovascular diseases.

North America region will lead the global renal denervation devices market during the forecast period 2025 to 2034.